CTRI/2021/12/038780进行中（未招募）未知
Randomized, Open-Labelled, Parallel Group, Three-Arm Clinical Trial on Effect of Ayurvedic Drug Formulation (Thyrogrit) Vs. Yogic Practices Vs. Conventional Drug (Levothyroxine) in Patients with Hypothyroidism.
Patanjali Research Institute governed by Patanjali Research Foundation Trust0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Diagnosed with Subclinical hypothyroidism.
- •Patients willing to participate in the study and ready to provide informed consent.
排除标准
- •Patients diagnosed with type of hypothyroidism other than Subclinical hypothyroidism.
- •Patients with age below 30 years and above 65 years.
- •Pregnant females.
- •Patients underwent recent thyroid surgery.
- •Patients used hormonal contraceptives in recent history of three months.
- •Alcohol and smoking addicted patients.
- •Patients hypersensitive to study medication and its composition.
- •Patients unwillingness or inability to follow the procedure outlined in protocol.
- •Patients who are mentally or legally incapable of understanding informed consent form.
- •Patients with slip disc, cervical spondylitis, severe back problems, recent surgical history are excluded in yogic intervention.
研究者
相似试验
进行中（未招募）
不适用
Pharmacodynamic effects of lixisenatide compared to liraglutide in patients with type 2 diabetes not adequately controlled with insulin glargine with or without metformin.Type 2 Diabetes mellitusMedDRA version: 15.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-000027-40-DESanofi-Aventis Recherche & Développement
进行中（未招募）
不适用
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsMeningococcal disease causes high rates of morbidity and mortality even among patients who receive early antibiotic treatment.EUCTR2014-004605-33-Outside-EU/EEAovartis Vaccines & Diagnostics, Inc.4,500
进行中（未招募）
1 期
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia GravisMedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersGeneralized Myasthenia GravisEUCTR2020-004085-19-BEargenx BV76
进行中（未招募）
1 期
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia GravisGeneralized Myasthenia GravisEUCTR2020-004085-19-HUargenx BV110
进行中（未招募）
1 期
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia GravisMedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersGeneralized Myasthenia GravisEUCTR2020-004085-19-NLargenx BV76